Lifeward Ltd., a leader in medical technology, has achieved CE mark approval for its ReWalk 7 Personal Exoskeleton, allowing for its commercial launch in the European Union. This milestone enables Lifeward to expand its presence in Europe, where 40% of its exoskeleton sales occur, primarily through its German subsidiary, Lifeward GmbH. The ReWalk 7 features innovations like cloud connectivity and customizable walking speeds, enhancing mobility for individuals with spinal cord injuries. With established reimbursement processes in Germany, Lifeward is poised for significant commercial growth in Europe and plans to replicate this successful model in other markets, including the United States.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524902-en) on September 08, 2025, and is solely responsible for the information contained therein.